Abstract: A belt drive monitoring system comprising a driver, a driven, the driver and driven connected by an endless member, a first magnetic member having a magnetic field attached to the driver, a second magnetic member having a magnetic field attached to the driven, a first sensor disposed to detect a changing magnetic field caused by passage of the first magnetic member, a second sensor disposed to detect a changing magnetic field caused by passage of the second magnetic member, a first transmitter configured to wirelessly transmit to a receiver a first data signal from the first sensor and a second transmitter configured to wirelessly transmit to the receiver a second data signal from the second sensor, and the receiver configured to manipulate the data signal whereby a system parameter is calculated and provided to a user.

Abstract: A system for detecting a vehicle traveling a designated direction of travel on a roadway includes a sign having a front surface and a back surface. The sign may include a sign boundary marker that is different in color than a color of the front surface. One or more light panels such as an LED light panel is affixed to the sign such as to its front surface. The light emitting elements may lie below a top plane of the light panel. A color of a top surface of the light panel matches a color on the front surface of the sign over which the light panel is placed. A vehicle motion detector or proximity detector is oriented in a direction and has a detection zone for detecting moving vehicles in proximity to the sign. The detector illuminates the lights of the light panel after detecting a moving vehicle in proximity to the sign.

Abstract: A belt drive monitoring system comprising a driver, a driven, the driver and driven connected by an endless member, a first magnetic member having a magnetic field attached to the driver, a second magnetic member having a magnetic field attached to the driven, a first sensor disposed to detect a changing magnetic field caused by passage of the first magnetic member, a second sensor disposed to detect a changing magnetic field caused by passage of the second magnetic member, a first transmitter configured to wirelessly transmit to a receiver a first data signal from the first sensor and a second transmitter configured to wirelessly transmit to the receiver a second data signal from the second sensor, and the receiver configured to manipulate the data signal whereby a system parameter is calculated and provided to a user.

Abstract: A system for detecting a vehicle traveling a designated direction of travel on a roadway includes a sign having a front surface and a back surface. The sign may include a sign boundary marker that is different in color than a color of the front surface. One or more light panels such as an LED light panel is affixed to the sign such as to its front surface. The light emitting elements may lie below a top plane of the light panel. A color of a top surface of the light panel matches a color on the front surface of the sign over which the light panel is placed. A vehicle motion detector or proximity detector is oriented in a direction and has a detection zone for detecting moving vehicles in proximity to the sign. The detector illuminates the lights of the light panel after detecting a moving vehicle in proximity to the sign.

Abstract: A process for preparing compounds of Formula (I) are described herein as well as key intermediates 1.

Abstract: A process of obtaining an enantiomerically enriched salt from a racemic mixture of a compound of the formula wherein R is hydrogen or benzyl.

Abstract: This present invention relates to a new and improved reductive amination process for the preparation of 3-azabicyclo[3.1.0]hexane derivatives and pharmaceutical compositions comprising such derivatives. The invention particularly relates to using such derivatives to treat certain disorders and conditions, including, for example, irritable bowel syndrome, drug addiction or dependency, alcohol addiction or dependency, depression, and eating disorders.

Abstract: A method for preparing particular pyrrole-carboxamides which selectively bind to GABAa receptors; which comprises reacting 1,3-cycloalkanediones with bromoethylacetate followed by reaction of the resulting product with an acid halide followed by reaction with an aromatic amine and finally with an amonium source at an elevated temperature.

Abstract: This invention provides compounds of formula I and pharmaceutically-acceptable salts thereof, where the substituents are defined in the specification, which are growth hormone secretogogues useful for treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength , mobility, maintenance of skin thickness, metabolic homeostatis or renal homeostasis. Compounds of formula I in combination with: a bisphosphonate such as alendronate; estrogen, estrogens, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions thereof are useful in treating osteoporosis.

Abstract: A method for preparing particular pyrrole-carboxamides which selectively bind to GABAa receptors; which comprises reacting 1,3-cycloalkanediones with bromoethylacetate followed by reaction of the resulting product with an acid halide followed by reaction with an aromatic amine and finally with an amonium source at an elevated temperature.

Abstract: This invention is directed to compounds of the formula 1

Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.

Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.

Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.

Abstract: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating would healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.

Abstract: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis.

Abstract: Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis.

Abstract: Liquid beverages for supplementation of dietary calcium are disclosed. The beverages of this invention use calcium glycerophosphate as the source of calcium, acidulants, vitamin C and optionally, vitamin D.

Abstract: A calcium supplement in solid form contains calcium glycerophosphate, vitamin D and vitamin C.